Keyphrases
Human Immunodeficiency Virus Type 1 (HIV-1)
100%
Molecular Mechanism
100%
Efavirenz
100%
Antiretroviral
100%
Serotonergic Activity
100%
Neuropsychiatric Adverse Events
40%
5-HT6 Receptor
30%
5-HT2A Receptor
20%
Serotonin 2A Receptor (5-HT2AR)
10%
Rodents
10%
Nave
10%
5-hydroxytryptamine
10%
5-HT3
10%
Pharmacological Profile
10%
Beta-blockers
10%
Receptor Density
10%
Prolonged Exposure
10%
Drugs of Abuse
10%
Serotonergic
10%
Partial Agonist
10%
Abuse Potential
10%
Nevirapine
10%
5-HT2B Receptor
10%
5-HT3 Receptor
10%
Highly Effective
10%
Emtricitabine
10%
Muscarinic Receptors
10%
Gi Signaling
10%
5-HT2C Antagonist
10%
Inverse Agonist
10%
Gq Signaling
10%
Mechanistic Perspective
10%
GABA Current
10%
Prescribed Dose
10%
Molecular Targets
10%
First-line Antiretroviral Therapy
10%
Behavioral Profile
10%
Psychopharmacology
10%
WHO Guidelines
10%
Monoamine Oxidase A (MAO-A)
10%
Zidovudine
10%
Schild Analysis
10%
M3 muscarinic Receptor
10%
Receptor Current
10%
Neuroscience
Human Immunodeficiency Virus
100%
Serotonergic
100%
Efavirenz
100%
5-HT6 Receptor
30%
Agonist
20%
5-HT2A Receptor
20%
Psychotomimetic
10%
5-HT2B Receptor
10%
Serotonin 3A Receptor
10%
Inverse Agonist
10%
Emtricitabine
10%
2,5-Dimethoxy-4-iodoamphetamine
10%
Muscarinic M1 Receptor
10%
Nevirapine
10%
5-HT2C Antagonists
10%
Zidovudine
10%
Receptor
10%
Monoamine Oxidase A
10%
Psychopharmacology
10%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Efavirenz
100%
Receptor
70%
Adverse Event
40%
Psychotomimetic
10%
Long Term Exposure
10%
Partial Agonist
10%
Nevirapine
10%
Emtricitabine
10%
Amine Oxidase (Flavin Containing) Isoenzyme A
10%
Zidovudine
10%
2,5-Dimethoxy-4-iodoamphetamine
10%
Inverse Agonist
10%
Muscarinic M1 Receptor
10%
Serotonin 2C Antagonist
10%
Molecular Target
10%
Serotonin 3A Receptor
10%
Psychopharmacology
10%